Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cH…
Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma
Estimated
~$10 – $6,250
Baylor College of MedicineNCT04288726
Phase 1
A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any…
MelanomaLymphomaSolid Tumor+2 more
Estimated
~$10 – $8,750
Merck Sharp & Dohme LLCNCT02332668
Phase 1
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to trea…
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
Estimated
~$10 – $7,500
MacroGenicsNCT05362773
Phase 1
MAC-CAR: A Phase 1B/II Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults With Poor-Risk Classical Hodgkin Lymphoma (cHL)
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and…
Classical Hodgkin Lymphoma
Estimated
~$10 – $6,250
New York Medical CollegeNCT06617286